PT  - JOURNAL ARTICLE
AU  - Murakhovskaya, Irina
AU  - Demasio, Kafui A.
TI  - Maternal Hematologic Conditions and Fetal/Neonatal Outcomes of Pregnancy
AID  - 10.1542/neo.22-2-e95
DP  - 2021 Feb 01
TA  - NeoReviews
PG  - e95--e103
VI  - 22
IP  - 2
4099  - http://neoreviews.aappublications.org/content/22/2/e95.short
4100  - http://neoreviews.aappublications.org/content/22/2/e95.full
SO  - NeoReviews2021 Feb 01; 22
AB  - Abbreviations:GP: glycoproteinHPA: human platelet antigenICTM: International Collaboration for Transfusion MedicineIVIG: intravenous immunoglobulinNAIT: neonatal alloimmune thrombocytopeniaPT: prothrombin timePTT: partial thromboplastin timeHematologic conditions in reproductive-age women can complicate pregnancy and the neonatal period. Affected pregnancies have a higher risk of severe morbidity and mortality. Coagulation factor changes that occur in the normal state of pregnancy can delay detection and recognition of a bleeding disorder in cases without an apparent bleeding history, thus hindering the appropriate management during gestation and the neonatal period. In addition, unique maternal immunologic changes occur during pregnancy, which are meant to protect the fetus who shares paternal antigens. Rarely, derangement of the maternal immune system may result in alloimmunization against fetal platelet antigens, leading to the development of fetal and/or neonatal thrombocytopenia. Bleeding and platelet disorders pose significant risk of intracranial hemorrhage for the fetus and newborn that is associated with significant morbidity and mortality. We discuss contemporary diagnosis and management of rare bleeding and platelet disorders in pregnancy and their effect on the neonatal period.